Research & KnowledgeEvent: September 8, 2026
Sleuth published a report showing that Novartis has gone all-in since 2017, with a commitment of over $12B in disclosed potential consideration across 13+ deals, including takeouts of AAA ($3.9B, brought Lutathera), Endocyte ($2.1B, brought Pluvicto), and Mariana Oncology ($1.75B), with Lutathera and Pluvicto generating $1.8B in sales through H1 2026.
Published
Signal category
Research & Knowledge
Quote
“This has come at the expense of other drug classes, such as ADCs or bispecifics, where Novartis has no late-stage assets.”
— Andrew Pannu|Sleuth team
Company
Sleuth
Sleuth helps strategic biopharma teams get to conviction faster, turning complex questions into clear answers - in hours
- Industry
- Software Development
- Location
- San Francisco, US
- Company size
- 21 employees
Sleuth replaces patchworks of database subscriptions, consulting engagements, and internal spreadsheets - whether your team runs the analysis or ours does.
Founded 2023